Six years ago, David Perry was one of the rock stars of the Web, the founding CEO of Chemdex-Ventro, one of the creators of the business-to-business e-marketplace concept. In just three years, he had built his company from scratch to 354 employees and an unaccountable $10 billion valuation. And then he stuck with it as the company unraveled, shutting down most of the businesses he'd built, and merging the remainder into what is now an OTC-traded software company.
Lessons Learned: David Perry, from Chemdex to Anacor
Six years ago, David Perry was one of the rock stars of the Web, the founding CEO of Chemdex-Ventro. He stuck with it as the company unraveled, shutting down most of the businesses he'd built, and merging the remainder into what is now an OTC-traded software company. Now he's applying the lessons he learned to his current company, Anacor Pharmaceuticals, a start-up which has discovered a small handful of now clinical-stage compounds.
More from Strategy
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
More from Business
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.